Positions

Overview

  • Dr. Stoll is a pediatric rheumatologist who earned his MD and PhD at Upstate Medical University (Syracuse, NY) in 2001, followed by completion of residency in pediatrics at the Long Island Jewish Medical Center in 2004 and fellowship in pediatric rheumatology at the Childrens Hospital Boston in 2007. At the completion of his fellowship, he took a staff position at the University of Texas at Southwestern Medical Center (Dallas, TX), where he earned an MSCS degree. In 2011, he moved to the University of Alabama at Birmingham, where he remains. During his fellowship, Dr. Stoll developed an interest in the clinical epidemiology of spondyloarthritis, publishing on age-based subgroups of juvenile psoriatic arthritis as well as risk factors for sacroiliitis in patients with pediatric spondyloarthritis. He subsequently turned his attention to the links between spondyloarthritis and inflammatory bowel disease and reported on use of fecal calprotectin as well as intestinal MRI to identify sub-clinical intestinal inflammation in children with spondyloarthritis. His current work focuses on the role of the intestinal and oral microbiota in the pathogenesis of spondyloarthritis.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Genetics, Prevotella, and the pathogenesis of rheumatoid arthritisLancet Rheumatology.  2:e375-e376. 2020
    2020 Identification of Prevotella Oralis as a possible target antigen in children with Enthesitis related arthritisClinical Immunology.  216. 2020
    2020 Psoriatic arthritis in childhood: A commentary on the controversyClinical Immunology.  214. 2020
    2020 Variability in magnetic resonance imaging interpretation of the pediatric sacroiliac joint.Arthritis Care and Research2020
    2020 Alpha-1 Antitrypsin Deficiency in an Infant With Polyarteritis Nodosa. 2020
    2020 Th17 reprogramming of T cells in systemic juvenile idiopathic arthritisJCI insight.  5. 2020
    2020 Microbial orchestra in juvenile idiopathic arthritis: Sounds of disarray?Immunological Reviews.  294:9-26. 2020
    2020 Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic LymphohistiocytosisArthritis and Rheumatology.  72:326-334. 2020
    2020 The Epigenetic Connection Between the Gut Microbiome in Obesity and DiabetesFrontiers in Genetics.  10. 2020
    2019 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated UveitisArthritis Care and Research.  71:703-716. 2019
    2019 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated UveitisArthritis and Rheumatology.  71:864-877. 2019
    2019 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and EnthesitisArthritis and Rheumatology.  71:846-863. 2019
    2019 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and EnthesitisArthritis Care and Research.  71:717-734. 2019
    2019 Akkermansia muciniphila is permissive to arthritis in the K/BxN mouse model of arthritisGenes and Immunity.  20:158-166. 2019
    2019 Emergent high fatality lung disease in systemic juvenile arthritisAnnals of the Rheumatic Diseases.  78:1722-1731. 2019
    2019 Standardizing terminology and assessment for orofacial conditions in juvenile idiopathic arthritis: International, multidisciplinary consensus-based recommendationsJournal of Rheumatology.  46:518-522. 2019
    2018 Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature 2018
    2018 Pediatric ocular lichen planus and lichen planopilaris: One new case and a review of the literaturePediatric Dermatology.  35:859-863. 2018
    2018 Risk factors for intraarticular heterotopic bone formation in the temporomandibular joint in Juvenile idiopathic arthritisJournal of Rheumatology.  45:1301-1307. 2018
    2018 Juvenile Psoriatic Arthritis: A Report from the GRAPPA 2017 Annual Meeting 2018
    2018 Pediatric rheumatology infusion center: Report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year 2018
    2018 Adiposity in juvenile psoriatic arthritisJournal of Rheumatology.  45:411-418. 2018
    2018 Age and fecal microbial strain-specific differences in patients with spondyloarthritis 2018
    2018 Defining the normal appearance of the temporomandibular joints by magnetic resonance imaging with contrast: A comparative study of children with and without juvenile idiopathic arthritis 2018
    2018 Temporomandibular joint arthritis in juvenile idiopathic arthritis, now what? 2018
    2017 Impact of genistein on the gut microbiome of humanized mice and its role in breast tumor inhibitionPLoS ONE.  12. 2017
    2017 Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: A retrospective study 2017
    2017 Isolated arthritis of the temporomandibular joint as the initial manifestation of juvenile idiopathic arthritisJournal of Rheumatology.  44:1632-1635. 2017
    2017 Association of Anti–3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis PatientsArthritis Care and Research.  69:1088-1094. 2017
    2017 Biologic therapies for refractory juvenile dermatomyositis: Five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America 2017
    2017 The juvenile psoriatic arthritis cohort in the CARRA registry: Clinical characteristics, classification, and outcomesJournal of Rheumatology.  44:342-351. 2017
    2016 Fecal metabolomics in pediatric spondyloarthritis implicate decreased metabolic diversity and altered tryptophan metabolism as pathogenic factorsGenes and Immunity.  17:400-405. 2016
    2016 The microbiota in pediatric rheumatic disease: Epiphenomenon or therapeutic target?Current Opinion in Rheumatology.  28:537-543. 2016
    2016 The microbiome in pediatric rheumatic diseases.The Rheumatologist.  10. 2016
    2016 Ustekinumab as a Therapeutic Option for Children with Refractory Enthesitis-Related Arthritis 2016
    2016 Gut microbiota-host interactions and juvenile idiopathic arthritis 2016
    2015 Magnetic resonance imaging findings following intraarticular infliximab therapy for refractory temporomandibular joint arthritis among children with juvenile idiopathic arthritisJournal of Rheumatology.  42:2155-2159. 2015
    2015 Novel method to collect medication adverse events in juvenile arthritis: Results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance projectArthritis Care and Research.  67:529-537. 2015
    2015 Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseasesJournal of Rheumatology.  42:541-546. 2015
    2015 Systemic and intra-articular anti-inflammatory therapy of temporomandibular joint arthritis in children with juvenile idiopathic arthritisSeminars in Orthodontics.  21:125-133. 2015
    2015 Temporomandibular joint arthritis in juvenile idiopathic arthritis: The last frontierInternational Journal of Clinical Rheumatology.  10:273-285. 2015
    2014 Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis 2014
    2014 Gut microbes, immunity, and spondyloarthritisClinical Immunology.  159:134-142. 2014
    2014 Treatment of juvenile idiopathic arthritis: A revolution in care 2014
    2014 Adding canakinumab to the childhood arthritis and rheumatology research alliance consensus treatment plans for systemic juvenile idiopathic arthritis: Comment on the article by DeWitt et alArthritis Care and Research.  66:1430-1431. 2014
    2014 Imaging of the temporomandibular joint in juvenile idiopathic arthritisArthritis Care and Research.  66:47-54. 2014
    2013 Treatment of Juvenile Idiopathic Arthritis in the Biologic AgeRheumatic Disease Clinics of North America.  39:751-766. 2013
    2013 High doses of infliximab in the management of juvenile idiopathic arthritisJournal of Rheumatology.  40:1749-1755. 2013
    2013 Safety and efficacy of intra-articular infliximab therapy for treatment-resistant temporomandibular joint arthritis in children: A retrospective studyRheumatology.  52:554-559. 2013
    2013 Shrinking lung syndrome as a manifestation of pleuritis: A new model based on pulmonary physiological studiesJournal of Rheumatology.  40:273-281. 2013
    2012 Mechanisms involved in the p62-73 idiopeptide-modulated delay of lupus nephritis in SNF1 miceLupus.  21:1552-1564. 2012
    2012 Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritisJournal of Rheumatology.  39:1880-1887. 2012
    2012 Intra-articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritisJournal of Oral and Maxillofacial Surgery.  70:1802-1807. 2012
    2012 Consensus treatment plans for new-onset systemic juvenile idiopathic arthritisArthritis Care and Research.  64:1001-1010. 2012
    2012 17β-Estradiol (E-2) administration to male (NZB × SWR)F 1 mice results in increased Id LNF 1-reactive memory T-lymphocytes and accelerated glomerulonephritisLupus.  21:288-301. 2012
    2012 MR enterography to evaluate sub-clinical intestinal inflammation in children with spondyloarthritis 2012
    2012 IgA transglutaminase levels in children with Juvenile Idiopathic Arthritis.Annals of paediatric rheumatology.  1:31-35. 2012
    2011 Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritisJournal of Rheumatology.  38:2274-2275. 2011
    2011 Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritisClinical and Experimental Rheumatology.  29:582-588. 2011
    2011 Psoriatic juvenile idiopathic arthritis: A tale of two subgroupsCurrent Opinion in Rheumatology.  23:437-443. 2011
    2011 Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritisClinical and Experimental Rheumatology.  29:322-330. 2011
    2011 Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory courseClinical and Experimental Rheumatology.  29:736-742. 2011
    2010 Validity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severityJournal of Clinical Epidemiology.  63:1358-1362. 2010
    2010 Spondyloarthritis in a pediatric population: Risk factors for sacroiliitisJournal of Rheumatology.  37:2402-2408. 2010
    2009 TNFα inhibitors may improve asthma symptoms: A case series of 12 patients with rheumatoid arthritis and asthma 2009
    2008 Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences 2008
    2008 Comparison of Vancouver and International League of Associations for Rheumatology classification criteria for juvenile psoriatic arthritisArthritis Care and Research.  59:51-58. 2008
    2007 Immunization with peptides derived from the idiotypic region of lupus-associated autoantibodies delays the development of lupus nephritis in the (SWR × NZB)F1 murine modelJournal of Autoimmunity.  29:30-37. 2007
    2006 Patients with juvenile psoriatic arthritis comprise two distinct populationsArthritis and Rheumatism.  54:3564-3572. 2006
    2006 Subpopulations within juvenile psoriatic arthritis: A review of the literatureClinical and Developmental Immunology.  13:377-380. 2006
    2004 Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: A study from a Children's Hospital Emergency Department and Urgent Care CenterJAMA Pediatrics.  158:671-675. 2004
    2004 Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF [2]Pediatric Nephrology.  19:120-121. 2004
    2003 Pheochromocytoma unmasked by imipramine in an 8-year-old girlPediatric Emergency Care.  19:174-177. 2003
    2002 Nephrolithiasis in a neonate with transient renal wasting of calcium and magnesiumPediatric Nephrology.  17:386-389. 2002
    2002 Molecular identification of pathogenetic IdLNF1+ autoantibody idiotypes derived from the (NZBxSWR)F1 model for systemic lupus erythematosusJournal of Autoimmunity.  19:87-101. 2002
    2000 Systemic lupus erythematosus - Messages from experimental modelsRheumatology.  39:18-27. 2000
    1996 Circadian variations of urinary electrolyte concentrations in preterm and term infantsJournal of Pediatrics.  128:253-256. 1996

    Book

    Year Title Altmetric
    2018 The microbiome in rheumatic diseases and infection 2018

    Chapter

    Year Title Altmetric
    2018 Inflammatory bowel disease.  251-274. 2018
    2018 Juvenile idiopathic arthritis.  221-237. 2018
    2018 Rheumatoid arthritis.  183-199. 2018
    2018 The microbiome: Past, present, and future.  3-11. 2018
    2018 The promise of personalized medicine.  465-474. 2018
    2014 Juvenile Idiopathic Arthritis.  1950-1963. 2014
    Extra-articular manifestations: inflammatory bowel disease

    Research Overview

  • My major research interest is the link between mucosal immunity and spondyloarthritis. Specifically, I am looking at the adaptive immune responses to enteric and oral organisms and the nature of the fecal and oral microbiota in patients with spondyloarthritis. I also am interested in the epidemiology, diagnosis, and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA).
  • Investigator On

  • A Randomized, Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept in Preventing Extension of Oligoarticular JIA (Limit-JIA)  awarded by Duke University 2020 - 2023
  • A Stakeholder-driven Comparative Effectiveness Study of Treatments to Prevent Coronary Artery Damage in Patients with Resistant Kawasaki Disease  awarded by University of California, San Diego 2019 - 2020
  • UAB Multidisciplinary Clinical Research Center (P60)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • UAB Multidisciplinary Clinical Research Center - Project 3  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • Observational Study of Pediatric Rheumatic Diseases : The CARRA Registry  awarded by Duke University 2015 - 2018
  • Childhood Arthritis and Rheumatology Research Alliance ("CARRA Registry")  awarded by Duke University 2012 - 2015
  • Childhood Arthritis and Research Alliance Network (CARRANet): Juvenile Dermatomyositis Consensus Treatment Plan  awarded by DUKE CLINICAL RESEARCH INSTITUTE 2013 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • Childhood Arthritis and Research Alliance Network (CARRANet): Juvenile Idiopathic Arthritis Consensus Treatment Plan  awarded by Duke University 2013 - 2014
  • Improved Understanding of the Biology and use of TNF Inhibition in Children with JIA  awarded by CHILDREN'S HOSPITAL MEDICAL CENTER (CINCINNATI) 2011 - 2013
  • Education And Training

  • Doctor of Medicine, Syracuse University 2001
  • Doctor of Philosophy in Immunology, Syracuse University 2001
  • Bachelor of Arts in Molecular Biochemistry, Wesleyan University 1994
  • Long Island Jewish Medical Center, Internship 2002
  • Long Island Jewish Medical Center, Residency 2004
  • Children's Hospital Boston, Postdoctoral Fellowship 2007
  • Full Name

  • Matthew Stoll